What questions should be asked and what key factors should be evaluated during an initial consultation for a patient being considered for tirzepatide (Zepbound) therapy?

Initial Consultation for Zepbound (Tirzepatide): Essential Questions and Key Assessment Factors

During an initial Zepbound consultation, you must stratify the patient's cardiovascular and kidney risk to determine if tirzepatide is the optimal choice, as patients at higher risk may require GLP-1 receptor agonists or SGLT2 inhibitors instead for proven mortality and cardiovascular benefits 1.

Critical Risk Stratification Questions

Cardiovascular and Kidney Risk Assessment

This is your most important initial determination:

• Does the patient have established cardiovascular disease? (prior MI, stroke, peripheral artery disease, coronary revascularization)
• Does the patient have chronic kidney disease? (eGFR <60, albuminuria)
• Does the patient have heart failure? (particularly with preserved ejection fraction)
• What is their diabetes duration and control? (HbA1c level, years since diagnosis)

Why this matters: If the patient has moderate-to-high cardiovascular or kidney risk, tirzepatide should NOT replace medications with proven cardiovascular and kidney benefits. If they're currently on a GLP-1 receptor agonist and you switch to tirzepatide, you MUST initiate or continue an SGLT2 inhibitor 1.

Obesity and Weight-Related Assessment

• Current BMI and baseline weight (tirzepatide produces mean 8.63 kg weight loss at ~90 kg baseline; higher baseline weights see greater absolute reductions) 1
• Weight-related comorbidities: obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease (MASLD), hypertension, dyslipidemia
• Previous weight loss attempts and their outcomes
• Patient's primary treatment goal: Is weight loss the priority, or cardiovascular/kidney protection?

Contraindications and Safety Screening

Absolute Contraindications

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia type 2 (MEN 2) 2

High-Risk Conditions Requiring Caution

• History of pancreatitis (not an absolute contraindication but requires careful consideration)
• History of severe gastrointestinal disease (gastroparesis, inflammatory bowel disease)
• Active gallbladder disease
• Severe renal impairment (assess eGFR)
• Pregnancy or planning pregnancy (must discontinue)

Current Medication Review

Critical Drug Interactions

• Is the patient currently on a GLP-1 receptor agonist? (semaglutide, liraglutide, dulaglutide) - CANNOT be combined with tirzepatide 1
• Insulin or sulfonylureas? (increased hypoglycemia risk; doses will need reduction) 2
• SGLT2 inhibitors? (CAN be combined; should be continued if patient has CV/kidney risk) 1

Patient Expectations and Tolerability Assessment

Gastrointestinal Tolerance Screening

Gastrointestinal adverse events are the primary reason for discontinuation:

• History of nausea, vomiting, or motion sickness?
• Previous experience with GLP-1 medications? (if intolerant before, may have similar issues)
• Occupation or lifestyle factors that would make nausea/vomiting particularly problematic

Expected adverse event rates from trials: Nausea (10-31%), diarrhea (7-23%), vomiting (2-12%), constipation (3-5%) 2. These are typically mild-to-moderate and occur primarily during dose escalation 3.

Treatment Commitment Assessment

• Can the patient commit to weekly subcutaneous injections?
• Financial considerations: Cost and insurance coverage (tirzepatide is expensive)
• Understanding of gradual dose escalation (starts at 2.5 mg weekly, increases every 4 weeks)
• Realistic weight loss expectations (mean 15-21% body weight loss over 72 weeks depending on dose) 3

Baseline Monitoring Parameters to Obtain

Laboratory Assessment

• HbA1c (if diabetic or prediabetic)
• Fasting glucose and lipid panel
• Comprehensive metabolic panel (renal function, liver enzymes)
• Thyroid function (baseline TSH)
• Serum bicarbonate (if considering combination with other medications)

Clinical Measurements

• Baseline weight and BMI
• Waist circumference
• Blood pressure
• Heart rate

Special Population Considerations

Prediabetes Screening

Tirzepatide dramatically reduces progression to type 2 diabetes: Only 1.3% developed diabetes over 3 years versus 13.3% with placebo (HR 0.07) 4. If the patient has prediabetes (HbA1c 5.7-6.4%), this is a major benefit to emphasize.

Obstructive Sleep Apnea

If the patient has moderate-to-severe OSA with obesity, tirzepatide shows significant benefits on both OSA metrics and cardiometabolic risk factors 5.

Common Pitfalls to Avoid

1. Starting tirzepatide in high CV/kidney risk patients without SGLT2 inhibitor coverage - This sacrifices proven mortality benefits for weight loss 1

2. Failing to reduce insulin/sulfonylurea doses - Leads to hypoglycemia during treatment initiation

3. Not counseling about gastrointestinal side effects - Primary cause of discontinuation (4.3-7.1% discontinuation rate) 3

4. Inadequate hydration counseling - Particularly important if patient is on insulin or sulfonylureas 2

5. Switching from GLP-1 agonist to tirzepatide in high-risk patients without adding SGLT2 inhibitor - Loses cardiovascular protection 1

Decision Algorithm Summary

For LOW cardiovascular/kidney risk patients with obesity: Tirzepatide is an excellent choice given superior weight loss effects 1

For MODERATE-to-HIGH cardiovascular/kidney risk patients:

• If weight loss is the priority AND patient accepts uncertain CV/kidney data: Use tirzepatide PLUS SGLT2 inhibitor 1
• If CV/kidney protection is the priority: Consider GLP-1 receptor agonist instead (higher certainty evidence for CV/kidney benefits) 1